Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.

The Annals of pharmacotherapy - 1 Sept 2017

Molino Suzanne, Martin Michelle T

Abstract excerpt

OBJECTIVE: To review the role and utility of baseline resistance testing with currently available and pipeline genotype 1 hepatitis C virus (HCV) treatment. DATA SOURCES: Authors reviewed liver meeting abstracts for data on currently-available and pipeline genotype 1 retreatment regimens from January 1, 2015, to March 23, 2017. Additional trials were identified from a review of clinicaltrials.gov using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials as Topic
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C

Share to Practice Guidelines as Topic

Share to Retreatment

Share to Sustained Virologic Response

Source

Identifiers

PMID: 28480743
DOI: 10.1177/1060028017704857

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.PMID 28480743Read ↗

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.Semantic proximity Read ↗

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Semantic proximity Read ↗

Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.Semantic proximity Read ↗

Interpretation and application of virological testing including resistance in chronic hepatitis B.Semantic proximity Read ↗

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.Semantic proximity Read ↗

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Semantic proximity Read ↗

Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland.Semantic proximity Read ↗

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.Semantic proximity Read ↗

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.Semantic proximity Read ↗

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Semantic proximity Read ↗

Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.Semantic proximity Read ↗

Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.